AI & Machine Learning in Biotechnology

Wave crashes after obesity trial tracks 1% dip in body weight over 6 months

Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive the stock down more than 50% despite the biotech hailing the data as positive.​Read More

Published

2 weeks ago

on

Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive the stock down more than 50% despite the biotech hailing the data as positive.​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version